Sangoma Announces Date of Second Quarter Fiscal Year 2023 2-02-2023, 02:12

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Evergreen Line selects ORBCOMM’s smart dry container solutions 20-10-2025, 19:00